Wall Street analysts support Abbott’s planned $890m acquisition of Cardiovascular Systems (CSI) as a relatively inexpensive way for Abbott to expand its presence in the peripheral intervention market.
Under the terms of the deal announced late on 8 February, Abbott has agreed to acquire CSI for $20 per share, for a total value of about $890m. The equity...